Fig. 4: Targeting effects of PD-1Ab21 on differentiation of TSCM-like cells by binding to PD-1+ T cells. | Nature Communications

Fig. 4: Targeting effects of PD-1Ab21 on differentiation of TSCM-like cells by binding to PD-1+ T cells.

From: Targeting IL-21 to tumor-reactive T cells enhances memory T cell responses and anti-PD-1 antibody therapy

Fig. 4: Targeting effects of PD-1Ab21 on differentiation of TSCM-like cells by binding to PD-1+ T cells.

a, b Naïve OT-1 cells were activated by OVA257-264 peptide for 2 d and then differentiated with different concentrations of cytokines or proteins for 3 d. T cell differentiation was analyzed by flow cytometry. a Representative dot-plots of TSCM differentiation with different concentrations of IL-21IgFc and PD-1Ab21 (left). Percentage of CD44lowCD62Lhigh CD8+ T cells was counted (right). b Naïve T cells isolated from LNs of WT or PD-1−/− mice were primed with anti-CD3 and anti-CD28 for 2 d, and then differentiated with the indicated concentrations of IL-21IgFc or PD-1Ab21. Percentage of CD44lowCD62Lhigh CD8+ T cells was counted. All data are presented as mean ± SD and representative of at least three independently performed experiments. Results were compared using two-way ANOVA followed by Tukey’s multiple comparison test. a **p = 0.0086. ****p < 0.0001. b *p = 0.0257, **p = 0.0082, ***p = 0.0001, ****p < 0.0001, n.s. not significant.

Back to article page